Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp increased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 174.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 21,349 shares of the company's stock after purchasing an additional 13,575 shares during the quarter. Mackenzie Financial Corp's holdings in Protagonist Therapeutics were worth $824,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Farallon Capital Management LLC grew its position in Protagonist Therapeutics by 1.2% in the 4th quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company's stock valued at $228,898,000 after acquiring an additional 69,000 shares during the last quarter. RTW Investments LP grew its position in Protagonist Therapeutics by 1.3% in the 4th quarter. RTW Investments LP now owns 5,498,545 shares of the company's stock valued at $212,244,000 after acquiring an additional 72,433 shares during the last quarter. BVF Inc. IL grew its position in Protagonist Therapeutics by 2.7% in the 4th quarter. BVF Inc. IL now owns 1,900,015 shares of the company's stock valued at $73,341,000 after acquiring an additional 49,848 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Protagonist Therapeutics by 6.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock valued at $53,758,000 after acquiring an additional 83,185 shares during the last quarter. Finally, Deep Track Capital LP purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter worth $38,600,000. Institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock traded up $2.29 during midday trading on Thursday, reaching $53.82. The company's stock had a trading volume of 947,103 shares, compared to its average volume of 890,746. The stock's 50-day simple moving average is $45.34 and its 200-day simple moving average is $42.81. Protagonist Therapeutics, Inc. has a 52-week low of $30.67 and a 52-week high of $60.60. The stock has a market capitalization of $3.34 billion, a P/E ratio of 20.23 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $28.32 million during the quarter, compared to analysts' expectations of $30.44 million. As a group, equities research analysts expect that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PTGX has been the subject of several research reports. The Goldman Sachs Group lowered their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, February 24th. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a report on Monday, March 3rd. Wall Street Zen cut Protagonist Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, May 31st. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Tuesday. Finally, JMP Securities restated a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $65.44.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CFO Asif Ali sold 24,903 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the transaction, the chief financial officer now directly owns 62,821 shares of the company's stock, valued at approximately $3,689,477.33. This represents a 28.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at $712,302.50. This represents a 23.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,173 shares of company stock worth $3,461,180. 4.90% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.